AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases
AbbVie and Calico Life Sciences extend their collaboration to 2025, focusing on age-related diseases like neurodegeneration and cancer. Since 2014, they've developed over 20 early-stage programs, advancing three targets to clinical trials. Both will contribute an additional $500 million, sharing costs and profits equally.
Reference News
AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases
AbbVie and Calico Life Sciences extend their collaboration to 2025, focusing on age-related diseases like neurodegeneration and cancer. Since 2014, they've developed over 20 early-stage programs, advancing three targets to clinical trials. Both will contribute an additional $500 million, sharing costs and profits equally.